Revvity

Revvity's predictability score of 60/100 is moderate, reflecting a company in a state of flux rather than stable, consistent operations. The significant strategic divestiture, which largely explains the -17.4% 3-year Revenue CAGR, introduces substantial uncertainty about future revenue trajectories and earnings stability.

While the healthcare sector generally benefits from somewhat resilient demand, Revvity's recent corporate actions make historical trends less indicative of future performance. The healthy TTM Free Cash Flow Margin of 17.5% does provide some measure of operational stability.

However, the dramatic 5-year Net Income CAGR of 48.3% suggests that earnings have been subject to considerable swings, possibly due to one-off events or the divestiture itself, rather than predictable organic growth. Investors will require clearer guidance on the go-forward business model's intrinsic stability.